BioMarin upgraded to Buy from Hold at Stifel Nicolaus Stifel Nicolaus upgraded BioMarin based on valuation, and its belief that the company's pipeline may produce better than expected results in FY13. The firm also sees the company as an attractive acquisition target in the near-term. Target $67.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.